ScholarIQanswers from OpenAlex
CAR-T cell therapy research
TopicLeading institutions, researchers & key papers
CAR-T cell therapy research is a topic indexed in ScholarIQ from OpenAlex.
What is known about CAR-T cell therapy research?
ScholarIQrecord summary
This cluster of papers focuses on Chimeric Antigen Receptor (CAR) T cell therapy, a form of immunotherapy that uses genetically engineered T cells to target and destroy cancer cells. The papers cover various aspects of CAR T cell therapy, including its application in treating leukemia, lymphoma, and solid tumors, the management of cytokine release syndrome associated with this therapy, and the long-term efficacy and safety of CAR T cell treatment.
How many works does CAR-T cell therapy research have?
ScholarIQindexed works
CAR-T cell therapy research has 429 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for CAR-T cell therapy research?
ScholarIQopenalex
The OpenAlex for CAR-T cell therapy research is on the source record.
What are the most-cited papers on CAR-T cell therapy research?
ScholarIQmost cited works
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R. Verneris, Heather E. Stefanski, Gary D. Myers, Muna Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta Schlis, Kara L. Davis, Paul L. Martin, Eneida R. Nemecek, Gregory A. Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Françoise Méchinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia A. Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh, Benjamin Izar, Sanjay M. Prakadan, Marc H. Wadsworth, Daniel J. Treacy, John J. Trombetta, Asaf Rotem, Christopher Rodman, Christine G. Lian, Gëorge F. Murphy, Mohammad Fallahi‐Sichani, Ken Dutton‐Regester, Jia‐Ren Lin, Ofir Cohen, Parin Shah, Diana Lu, Alex S. Genshaft, Travis K. Hughes, Carly G.K. Ziegler, Samuel W. Kazer, Aleth Gaillard, Kellie E. Kolb, Alexandra–Chloé Villani, Cory M. Johannessen, Aleksandr Andreev, Eliezer M. Van Allen, Monica M. Bertagnolli, Peter K. Sorger, Ryan J. Sullivan, Keith T. Flaherty, Dennie T. Frederick, Judit Jané‐Valbuena, Charles H. Yoon, Orit Rozenblatt–Rosen, Alex K. Shalek, Aviv Regev, Levi A. Garraway
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
S. Hacein-Bey-Abina, Christof von Kalle, Manfred Schmidt, Matthew P. McCormack, N. M. Wulffraat, Philippe Leboulch, Apiradee Lim, Cameron S. Osborne, Robert Pawliuk, Estelle Morillon, Ricardo U. Sorensen, A. Förster, Peter Fraser, J. I. Cohen, Geneviève de Saint Basile, Ian E. Alexander, Uwe Wintergerst, Thierry Frébourg, Alain Aurias, Dominique Stoppa‐Lyonnet, Serge Romana, I Radford-Weiss, Fabian Gross, F Valensi, Éric Delabesse, Elizabeth Macintyre, F Sigaux, Jean Soulier, Lily E. Leiva, Manuela Wissler, Claudia Prinz, Terence H. Rabbitts, Françoise Le Deist, Alain Fischer, Marina Cavazzana
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, Yongzhi Cui, Cindy Delbrook, Steven A. Feldman, Terry J. Fry, Rimas J. Orentas, Marianna Sabatino, Nirali N. Shah, Seth M. Steinberg, D. Stroncek, Nick Tschernia, Constance M. Yuan, Hua Zhang, Ling Zhang, Steven A. Rosenberg, Alan S. Wayne, Crystal L. Mackall
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James Chih‐Hsin Yang, Richard M. Sherry, Richard E. Royal, Suzanne L. Topalian, Udai S. Kammula, Nicholas P. Restifo, Zhili Zheng, Azam Nahvi, Christiaan R. de Vries, Linda Rogers-Freezer, Sharon Mavroukakis, Steven A. Rosenberg
Where is CAR-T cell therapy research research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on CAR-T cell therapy research is open access?
ScholarIQopen access share
73%OPEN ACCESS